ATE295362T1
(de)
|
2001-01-02 |
2005-05-15 |
Hoffmann La Roche |
Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten
|
WO2002088079A2
(en)
|
2001-05-01 |
2002-11-07 |
Bristol-Myers Squibb Company |
Dual inhibitors of pde 7 and pde 4
|
US7105667B2
(en)
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
ES2427646T5
(es)
*
|
2005-05-09 |
2017-08-22 |
Ono Pharmaceutical Co., Ltd. |
Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
|
US20080051387A1
(en)
|
2006-06-09 |
2008-02-28 |
Yuelian Xu |
Tetrahydropyrido[3,4-d]pyrimidines and related analogues
|
US9259426B2
(en)
|
2006-07-20 |
2016-02-16 |
Gilead Sciences, Inc. |
4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
WO2008080056A2
(en)
|
2006-12-21 |
2008-07-03 |
Sloan-Kettering Institute For Cancer Research |
Pyridazinones and furan-containing compounds
|
WO2008103470A2
(en)
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
WO2009047255A1
(en)
|
2007-10-09 |
2009-04-16 |
Ucb Pharma, S.A. |
Heterobicyclic compounds as histamine h4-receptor antagonists
|
EP2318377B1
(en)
|
2008-07-31 |
2013-08-21 |
Genentech, Inc. |
Pyrimidine compounds, compositions and methods of use
|
WO2010120996A1
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
CA2759614C
(en)
|
2009-04-22 |
2017-09-19 |
Janssen Pharmaceutica Nv |
Azetidinyl diamides as monoacylglycerol lipase inhibitors
|
US20130029978A1
(en)
|
2009-12-25 |
2013-01-31 |
Mochida Pharmaceutical Co., Ltd. |
Novel aryl urea derivative
|
AU2010339456A1
(en)
|
2009-12-30 |
2012-07-05 |
Celgene Avilomics Research, Inc. |
Ligand-directed covalent modification of protein
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
WO2014011973A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of Columbia University In The City Of New York |
Quinazolinone-based oncogenic-ras-selective lethal compounds and their use
|
WO2014152588A1
(en)
|
2013-03-15 |
2014-09-25 |
Araxes Pharma Llc |
Covalent inhibitors of kras g12c
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
UA119971C2
(uk)
|
2013-10-10 |
2019-09-10 |
Араксіс Фарма Ллк |
Інгібітори g12c kras
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
MA40074A
(fr)
|
2014-05-30 |
2015-12-03 |
Univ Columbia |
Composés liant ras multivalents
|
WO2016025650A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049565A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions and methods for inhibition of ras
|
AR102094A1
(es)
|
2014-09-25 |
2017-02-01 |
Araxes Pharma Llc |
Inhibidores de proteínas kras con una mutación g12c
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
US10017540B2
(en)
|
2015-03-11 |
2018-07-10 |
California Institute Of Technology |
Cyclic peptide binder against oncogenic K-Ras
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
WO2016172692A1
(en)
|
2015-04-24 |
2016-10-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Mutant kras inhibitors
|
KR20180017013A
(ko)
|
2015-05-06 |
2018-02-20 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
K-Ras 조절제
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
US20180273577A1
(en)
|
2015-09-24 |
2018-09-27 |
Ionis Pharmaceuticals, Inc. |
Modulators of kras expression
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
JP6953400B2
(ja)
|
2015-10-22 |
2021-10-27 |
ザ スクリプス リサーチ インスティテュート |
システイン反応性プローブとその使用
|
WO2017080980A1
(en)
|
2015-11-09 |
2017-05-18 |
Astrazeneca Ab |
Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
|
WO2017079864A1
(en)
|
2015-11-12 |
2017-05-18 |
Hangzhou Yier Biotech Co., Ltd. |
Treatment of cancers related to chronically active ras
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
US20170283445A1
(en)
|
2016-04-05 |
2017-10-05 |
University Of South Carolina |
Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
|
SG11201810171SA
(en)
|
2016-05-18 |
2018-12-28 |
Mirati Therapeutics Inc |
Kras g12c inhibitors
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
WO2018098352A2
(en)
*
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
WO2018102452A2
(en)
|
2016-11-30 |
2018-06-07 |
Bantam Pharmaceutical, Llc |
Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
|
MX2019006299A
(es)
|
2016-11-30 |
2019-11-12 |
Bantam Pharmaceutical Llc |
Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
|
CA3047125A1
(en)
|
2016-12-15 |
2018-06-21 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
EP3878850A1
(en)
|
2016-12-22 |
2021-09-15 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
EP4001269A1
(en)
|
2016-12-22 |
2022-05-25 |
Amgen Inc. |
Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
US10344026B2
(en)
|
2017-01-18 |
2019-07-09 |
Nantbio, Inc. |
Compositions and methods of targeting mutant K-ras
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
JP2020505395A
(ja)
|
2017-01-26 |
2020-02-20 |
アラクセス ファーマ エルエルシー |
縮合n−複素環式化合物およびその使用方法
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
BR112019021899A2
(pt)
|
2017-04-20 |
2020-08-18 |
The Regents Of The University Of California |
moduladores de k-ras
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
US10647715B2
(en)
*
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
ES2944547T3
(es)
*
|
2017-11-15 |
2023-06-22 |
Mirati Therapeutics Inc |
Inhibidores de KRas G12C
|
US11545829B2
(en)
|
2018-07-31 |
2023-01-03 |
Honda Motor Co., Ltd. |
Power prediction system, power prediction device, power prediction method, program, and storage medium
|
CN113038342B
(zh)
|
2018-09-30 |
2022-10-14 |
荣耀终端有限公司 |
音频播放电路和终端
|
CN111193490A
(zh)
|
2018-11-14 |
2020-05-22 |
天津大学 |
散热结构、带散热结构的体声波谐振器、滤波器和电子设备
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
US20220193242A1
(en)
|
2019-02-07 |
2022-06-23 |
The Regents Of The University Of California |
Immunophilin-dependent inhibitors and uses thereof
|
EP3924687A4
(en)
|
2019-02-11 |
2022-11-02 |
Mesomat Inc. |
SENSING FIBERS FOR STRUCTURAL STRESS MONITORING
|
KR20200100429A
(ko)
|
2019-02-18 |
2020-08-26 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
|
GB2613715B
(en)
|
2019-02-20 |
2023-12-06 |
Fred Hutchinson Cancer Center |
Binding proteins specific for RAS neoantigens and uses thereof
|
GB201902392D0
(en)
|
2019-02-21 |
2019-04-10 |
Cambridge Entpr Ltd |
Modular binding proteins
|
US20220313700A1
(en)
|
2019-02-26 |
2022-10-06 |
Cell Response, Inc. |
Methods for treating map3k8 positive cancers
|
WO2020177629A1
(zh)
|
2019-03-01 |
2020-09-10 |
劲方医药科技(上海)有限公司 |
螺环取代的嘧啶并环类化合物,其制法与医药上的用途
|
MX2021010674A
(es)
|
2019-03-05 |
2021-09-28 |
Astrazeneca Ab |
Compuestos triciclicos condensados utiles como agentes anticancerigenos.
|
WO2020176963A1
(en)
|
2019-03-05 |
2020-09-10 |
Questor Technology Inc. |
Gas incinerator system
|
US20220118018A1
(en)
|
2019-03-06 |
2022-04-21 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
WO2020198125A1
(en)
|
2019-03-22 |
2020-10-01 |
Icahn School Of Medicine At Mount Sinai |
Methods for treating colorectal cancer
|
CA3134825A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
US20220154189A1
(en)
|
2019-03-29 |
2022-05-19 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
KR102222693B1
(ko)
|
2019-04-04 |
2021-03-04 |
금정제약 주식회사 |
H-rev107 유래 펩타이드의 신규한 용도
|
WO2020214537A1
(en)
|
2019-04-15 |
2020-10-22 |
Tosk, Inc. |
Modulators of ras gtpase
|
US20200335182A1
(en)
|
2019-04-16 |
2020-10-22 |
Uratim Ltd. |
Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions
|
US20220251109A1
(en)
|
2019-04-28 |
2022-08-11 |
Genfleet Therapeutics (Shanghai) Inc. |
Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof
|
CN114072397A
(zh)
|
2019-05-10 |
2022-02-18 |
德西费拉制药有限责任公司 |
杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法
|
PL3966207T3
(pl)
|
2019-05-10 |
2024-03-04 |
Deciphera Pharmaceuticals, Llc |
Fenyloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
|
CA3138123A1
(en)
|
2019-05-13 |
2020-11-19 |
Novartis Ag |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
JOP20210304A1
(ar)
|
2019-05-14 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
|
SG11202112790SA
(en)
|
2019-05-20 |
2021-12-30 |
California Inst Of Techn |
Kras g12c inhibitors and uses thereof
|
EP3972972A1
(en)
|
2019-05-21 |
2022-03-30 |
Amgen Inc. |
Solid state forms
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
CN112585129B
(zh)
|
2019-05-21 |
2022-03-01 |
益方生物科技(上海)股份有限公司 |
杂环化合物,其制备方法和用途
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
US20220306688A1
(en)
|
2019-06-07 |
2022-09-29 |
Emory University |
KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto
|
CN114269715A
(zh)
|
2019-06-12 |
2022-04-01 |
范德比尔特大学 |
作为氨基酸转运抑制剂的二苄基胺
|
WO2020252353A1
(en)
|
2019-06-12 |
2020-12-17 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
CN114040914A
(zh)
|
2019-07-01 |
2022-02-11 |
江苏恒瑞医药股份有限公司 |
喹唑啉酮类衍生物、其制备方法及其在医药上的应用
|
EP4011886A4
(en)
|
2019-08-02 |
2023-07-26 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
TETRACYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF
|
CN112341457A
(zh)
|
2019-08-07 |
2021-02-09 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
CN114174298B
(zh)
|
2019-08-14 |
2023-08-01 |
正大天晴药业集团南京顺欣制药有限公司 |
哒嗪酮并嘧啶类衍生物及其医药用途
|
CN112390797A
(zh)
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
CN114222743A
(zh)
|
2019-08-16 |
2022-03-22 |
劲方医药科技(上海)有限公司 |
氧代六元环并嘧啶类化合物,其制法与医药上的用途
|
KR20220050143A
(ko)
|
2019-08-22 |
2022-04-22 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
Kras-관련 암 치료 방법
|
WO2021037018A1
(zh)
|
2019-08-26 |
2021-03-04 |
南京创济生物医药有限公司 |
二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
|
MX2022002465A
(es)
|
2019-08-29 |
2022-05-19 |
Mirati Therapeutics Inc |
Inhibidores de kras g12d.
|
US20230172914A1
(en)
|
2019-09-06 |
2023-06-08 |
Wellmarker Bio Co., Ltd. |
Biomarker-based therapeutic composition
|
WO2021043322A1
(zh)
|
2019-09-06 |
2021-03-11 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
CN114375197A
(zh)
|
2019-09-10 |
2022-04-19 |
小利兰·斯坦福大学理事会 |
治疗kras突变癌症的方法
|
TW202124374A
(zh)
|
2019-09-13 |
2021-07-01 |
美商拜歐斯瑞克斯公司 |
Ras蛋白降解劑、其醫藥組合物及其治療應用
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
CN116947885A
(zh)
|
2019-09-20 |
2023-10-27 |
上海济煜医药科技有限公司 |
稠合吡啶酮类化合物及其制备方法和应用
|
US20230010886A1
(en)
|
2019-09-23 |
2023-01-12 |
Suzhou Puhe BioPharma Co., Ltd. |
Shp2 inhibitors and uses thereof
|
CN114761012A
(zh)
|
2019-09-24 |
2022-07-15 |
米拉蒂治疗股份有限公司 |
组合疗法
|
TW202115062A
(zh)
|
2019-09-25 |
2021-04-16 |
大陸商北京加科思新藥研發有限公司 |
Kras突變蛋白抑制劑
|
US20220389021A1
(en)
|
2019-09-29 |
2022-12-08 |
Beigene, Ltd. |
Inhibitors of kras g12c
|
WO2021063346A1
(zh)
|
2019-09-30 |
2021-04-08 |
上海迪诺医药科技有限公司 |
Kras g12c抑制剂及其应用
|
CN114555586B
(zh)
|
2019-10-10 |
2023-06-23 |
信达生物制药(苏州)有限公司 |
Krasg12c蛋白抑制剂及其制备方法和用途
|
JP6754125B1
(ja)
|
2019-10-15 |
2020-09-09 |
学校法人東京理科大学 |
Brap2作用増強剤
|
US20240139193A1
(en)
|
2019-10-15 |
2024-05-02 |
Amgen Inc. |
Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
|
CA3154841A1
(en)
|
2019-10-23 |
2021-04-29 |
Yong Je Shin |
Bicyclic compound and use thereof
|
CN112694475A
(zh)
|
2019-10-23 |
2021-04-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
EP4048671A1
(en)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
CR20220230A
(es)
|
2019-10-28 |
2022-06-15 |
Merck Sharp & Dohme |
Inhibidores de pequeñas moléculas de mutante g12c de kras
|
JP2023502891A
(ja)
|
2019-10-30 |
2023-01-26 |
▲勁▼方医▲薬▼科技(上海)有限公司 |
置換された複素環-環系化合物、その調製方法及び医薬への応用
|
WO2021084765A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd |
4-aminobut-2-enamide derivatives and salts thereof
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
EP4055028A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN113286794B
(zh)
|
2019-11-04 |
2024-03-12 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
AU2020379734A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005357A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
CN112778301A
(zh)
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
CA3159931A1
(en)
|
2019-11-07 |
2021-05-14 |
Chugai Seiyaku Kabushiki Kaisha |
Cyclic peptide compound having kras inhibitory action
|
WO2021093758A1
(zh)
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co Ltd |
NOVEL PHENOLIC COMPOUND OR SALT THEREOF
|
WO2021104431A1
(zh)
|
2019-11-29 |
2021-06-03 |
苏州信诺维医药科技股份有限公司 |
Kras g12c抑制剂化合物及其用途
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
JP7480298B2
(ja)
|
2019-12-02 |
2024-05-09 |
シャンハイ インリー ファーマシューティカル カンパニー リミテッド |
酸素含有複素環化合物、その製造方法及び使用
|
WO2021113595A1
(en)
|
2019-12-06 |
2021-06-10 |
Beta Pharma, Inc. |
Phosphorus derivatives as kras inhibitors
|
WO2021120045A1
(en)
|
2019-12-18 |
2021-06-24 |
InventisBio Co., Ltd. |
Heterocyclic compounds, preparation methods and uses thereof
|
WO2021126799A1
(en)
|
2019-12-18 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Macrocyclic peptides as potent inhibitors of k-ras g12d mutant
|
MX2022007527A
(es)
|
2019-12-19 |
2022-07-19 |
Jacobio Pharmaceuticals Co Ltd |
Inhibidores de proteinas kras mutantes.
|
CN114761408B
(zh)
|
2019-12-19 |
2023-09-15 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
WO2021121397A1
(zh)
|
2019-12-19 |
2021-06-24 |
首药控股(北京)股份有限公司 |
取代的炔基杂环化合物
|
TR201920922A2
(tr)
|
2019-12-20 |
2020-06-22 |
Ankara Ueniversitesi |
3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
CA3162106A1
(en)
|
2019-12-27 |
2021-07-01 |
Yuli Xie |
Spiro ring-containing quinazoline compound
|
CN113045565A
(zh)
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
WO2021139678A1
(zh)
|
2020-01-07 |
2021-07-15 |
广州百霆医药科技有限公司 |
吡啶并嘧啶类kras g12c突变蛋白抑制剂
|
CN113087700B
(zh)
|
2020-01-08 |
2023-03-14 |
苏州亚盛药业有限公司 |
螺环四氢喹唑啉
|
EP4087843A1
(en)
|
2020-01-10 |
2022-11-16 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
WO2021143693A1
(zh)
|
2020-01-13 |
2021-07-22 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
KR102382613B1
(ko)
|
2020-01-15 |
2022-04-06 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물
|
KR102396930B1
(ko)
|
2020-01-15 |
2022-05-12 |
한국과학기술연구원 |
피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
CN115003668A
(zh)
|
2020-01-21 |
2022-09-02 |
南京明德新药研发有限公司 |
作为kras抑制剂的大环类化合物
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
US20230099858A1
(en)
|
2020-02-20 |
2023-03-30 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as kras inhibitors
|
TW202140450A
(zh)
|
2020-02-24 |
2021-11-01 |
大陸商泰勵生物科技(上海)有限公司 |
用於癌症治療的kras抑制劑
|
CN114845997B
(zh)
|
2020-02-24 |
2024-03-29 |
上海喆邺生物科技有限公司 |
芳香类化合物及其在制备抗肿瘤药物中的应用
|
US20210292330A1
(en)
|
2020-02-28 |
2021-09-23 |
Erasca, Inc. |
Pyrrolidine-fused heterocycles
|
CN114901663A
(zh)
|
2020-03-02 |
2022-08-12 |
上海喆邺生物科技有限公司 |
一类芳香杂环类化合物及其在药物中的应用
|
EP4115887A1
(en)
|
2020-03-03 |
2023-01-11 |
Wellmarker Bio Co., Ltd. |
Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present
|
JP2023515691A
(ja)
|
2020-03-05 |
2023-04-13 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン |
Egfr、kras、braf、および他の標的の阻害剤およびそれらの使用
|
CN115768423A
(zh)
|
2020-03-05 |
2023-03-07 |
密歇根大学董事会 |
Egfr、kras、braf和其他靶标的抑制剂及其用途
|
JP2023517995A
(ja)
|
2020-03-12 |
2023-04-27 |
徳昇済医薬(無錫)有限公司 |
ピリミドヘテロ環式化合物およびその応用
|
TW202144345A
(zh)
|
2020-03-17 |
2021-12-01 |
大陸商北京加科思新藥研發有限公司 |
Kras突變蛋白抑制劑
|
WO2021190467A1
(zh)
|
2020-03-25 |
2021-09-30 |
微境生物医药科技(上海)有限公司 |
含螺环的喹唑啉化合物
|
KR20220164015A
(ko)
|
2020-04-03 |
2022-12-12 |
메드샤인 디스커버리 아이엔씨. |
옥타하이드로피라지노디아자나프티리딘 디온 화합물
|
JP2023521698A
(ja)
|
2020-04-06 |
2023-05-25 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
Krasの標的化分解のための化合物及び方法
|
CN115244058A
(zh)
|
2020-04-08 |
2022-10-25 |
江苏恒瑞医药股份有限公司 |
嘧啶并二环类衍生物、其制备方法及其在医药上的应用
|
JP2023522202A
(ja)
|
2020-04-16 |
2023-05-29 |
インサイト・コーポレイション |
融合三環式kras阻害剤
|
WO2021216770A1
(en)
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
EP4138875A1
(en)
|
2020-04-23 |
2023-03-01 |
The Regents of the University of California |
Ras inhibitors and uses thereof
|
EP4139299A1
(en)
|
2020-04-24 |
2023-03-01 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
CA3177261A1
(en)
|
2020-04-29 |
2021-11-04 |
Shanghai Ringene Biopharma Co., Ltd. |
Benzothiazolyl biaryl compound, and preparation method and use
|
TW202200563A
(zh)
|
2020-04-29 |
2022-01-01 |
中國商北京泰德製藥股份有限公司 |
喹喔啉酮衍生物作為kras g12c突變蛋白的不可逆抑制劑
|
WO2021219072A1
(zh)
|
2020-04-30 |
2021-11-04 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
CN113666923A
(zh)
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
WO2021236475A1
(en)
|
2020-05-18 |
2021-11-25 |
Asinex Corporation |
Compounds that inhibit asparagine synthetase and their methods of use
|
TWI799871B
(zh)
|
2020-05-27 |
2023-04-21 |
大陸商勁方醫藥科技(上海)有限公司 |
三環并環類化合物,其製法與醫藥上的用途
|
AU2021280351A1
(en)
|
2020-05-29 |
2023-01-05 |
Syros Pharmaceuticals, Inc. |
Methods of treating cancer in patients with an anomalous KRAS gene or deletions within chromosome 9
|
BR112022023462A2
(pt)
|
2020-06-02 |
2022-12-20 |
Boehringer Ingelheim Int |
2-amino-3-ciano tiofenos anulados e derivados para o tratamento de câncer
|
JP2023528903A
(ja)
|
2020-06-04 |
2023-07-06 |
アンテンジーン・ディスカバリー・リミテッド |
Kras g12cタンパク質阻害剤およびその使用
|
CN115768427A
(zh)
|
2020-06-04 |
2023-03-07 |
皮莱环球有限责任公司 |
癌症疗法中用于靶向降解不可靶向的kras的新型小分子
|
WO2021248082A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248079A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248095A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248083A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248090A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021252339A1
(en)
|
2020-06-08 |
2021-12-16 |
Accutar Biotechnology, Inc. |
Substituted purine-2,6-dione compounds as kras inhibitors
|
WO2021249563A1
(zh)
|
2020-06-12 |
2021-12-16 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
WO2021257828A1
(en)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
WO2021259331A1
(zh)
|
2020-06-24 |
2021-12-30 |
南京明德新药研发有限公司 |
八元含n杂环类化合物
|
JP2023531269A
(ja)
|
2020-06-30 |
2023-07-21 |
インベンティスバイオ カンパニー リミテッド |
キナゾリン化合物、その製造方法および用途
|
EP4182313A1
(en)
|
2020-07-16 |
2023-05-24 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
TW202214608A
(zh)
|
2020-07-20 |
2022-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用
|
JP2023531503A
(ja)
|
2020-08-02 |
2023-07-24 |
上▲海▼▲哲▼▲イェ▼生物科技有限公司 |
抗腫瘍薬物における芳香族化合物及びその用途
|
US20230339976A1
(en)
|
2020-08-04 |
2023-10-26 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
WO2022028492A1
(en)
|
2020-08-05 |
2022-02-10 |
Beigene, Ltd. |
Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors
|
US20230303551A1
(en)
|
2020-08-13 |
2023-09-28 |
Albert Einstein College Of Medicine |
N-cyclyl-sulfonamides useful for inhibiting raf
|